Carbon Dioxide Versus Iodine Contrast for Endovascular Revascularization of Aortoiliac Occlusive Disease

Aortoiliac Occlusive Disease Clinical Trial

Official title:

Carbon Dioxide Versus Iodine Contrast Medium for Endovascular Revascularization of Aortoiliac Occlusive Disease: A Two Center Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04458714
• Other study ID #: zu-irb#6036/16-3-2015
• Status: Completed
• Phase: N/A
• Start date: July 1, 2015
• Est. completion date: January 15, 2020

Study information

• Verified date: July 2020
• Source: Zagazig University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

From July 2015 to July 2018, 64 patients with aortoiliac occlusive disease who were eligible for endovascular treatment and lacked contraindications to either iodine contrast or carbon dioxide (CO2) were randomized into the carbon dioxide CO2 group(32) or iodine contrast medium(ICM) group(32) were subjected to aortoiliac angioplasty. The primary outcome was the quality of image as the sole contrast agent used in interventions. The secondary outcomes were technical success rate and the safety of procedure.

Description:

Sampling The sample size was calculated by the intuitional review board statistician using open epi based on the RCT done by Mendes et al. Power of study as set at 80% and confidence interval set at 95%. The sample size was calculated to be 64 cases, 32 in each group.

Randomization All patients who qualified for the inclusion and exclusion criteria were offered to participate in the trial after explaining all the details involved with the potential benefits and risks of both contrast mediums. Patients who agreed were asked to sign an informed consent. After patient data input was done, randomization was computer generated in the vascular surgery department in Zagazig university hospitals. Computer generated random numbers were created with the use of randomly permuted blocks with two block sizes; after which they were secured in consecutive numbered envelopes and group allocation was independent of time and person delivering the treatment. Single blinding was used to recruit the patients. The patients were randomized into the following two arms: a CO2 group (treatment arm) and an ICM group (control arm) according to the contrast medium selected for the intervention. Group I included 32 patients who were randomized for using CO2 as the contrast medium. Group II: involved 32 patients who were randomized for using iodine contrast medium (ICM).

Postoperative assessment and follow-up The endovascular equipment used in each intervention and the volumes of contrast used were accurately documented for analysis. Immediately after the operation all patients in both arms received intravenous fluids pre and post intervention following a local guideline for renal protection.¬ Patients were discharged the next day and outpatient renal functions were repeated 3 days post procedure, 1 week and 1 month. We analyzed creatinine levels between the two groups during the pre- and post-operative periods. Any elevation of serum creatinine (Scr) of more than 25% or ≥0.5 mg/dl is defined as contrast induced nephropathy (CIN). Patients were followed up for 1 year. One patient from the CO2 group decided to withdraw from the trial during the follow up period and was excluded from the follow up analysis.

Imaging from all cases were analyzed on conclusion of the study. The images were reviewed by two independent observers (radiologists with > 5 years of experience in performing endovascular procedures) blinded to treatment arm. Image quality was assessed using Likert rating scale ranging from 1 (very poor) to 5 (very good) for each image.18 A score of 1 was defined as poor quality with loss of delineation of the vessel. A score of 2 was considered below average with poor delineation of the vessel, a score of 3 is for average quality image and medium delineation of the vessel, a score of 4 was considered good quality with clear delineation of the vessel and a score of 5 was considered very good quality with very clear delineation of the vessel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: January 15, 2020
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with aortoiliac arteries atherosclerotic disease (with arterial atherosclerotic disease classified as Trans-Atlantic Inter-Society Consensus (TASC) A, B and C, (classified by CT angiography)

• Patients with good distal runoff

• Patients suitable for either types of contrast ICM or CO2 (No history of allergy to contrast and normal kidney functions)

Exclusion Criteria:

• Patients with TASC D aortoiliac lesions

• Patients requiring femoral endartectomy

• Patient s with significant multilevel distal disease

• Patients suffering from severe chronic obstructive lung disease, chronic kidney failure, heart failure, or pregnancy.

• Patients younger than 18 years

Related Conditions & MeSH terms

• Aortoiliac Occlusive Disease
• Leriche Syndrome

Intervention

Procedure:
• Aortoiliac angioplasty
In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Zagazig University

References & Publications (3)

de Almeida Mendes C, de Arruda Martins A, Teivelis MP, Kuzniec S, Nishinari K, Krutman M, Halpern H, Wolosker N. Carbon dioxide is a cost-effective contrast medium to guide revascularization of TASC A and TASC B femoropopliteal occlusive disease. Ann Vasc Surg. 2014 Aug;28(6):1473-8. doi: 10.1016/j.avsg.2014.03.021. Epub 2014 Apr 3. — View Citation

Fujihara M, Kawasaki D, Shintani Y, Fukunaga M, Nakama T, Koshida R, Higashimori A, Yokoi Y; CO2 Angiography Registry Investigators. Endovascular therapy by CO2 angiography to prevent contrast-induced nephropathy in patients with chronic kidney disease: a prospective multicenter trial of CO2 angiography registry. Catheter Cardiovasc Interv. 2015 Apr;85(5):870-7. doi: 10.1002/ccd.25722. Epub 2014 Nov 21. — View Citation

Sharafuddin MJ, Marjan AE. Current status of carbon dioxide angiography. J Vasc Surg. 2017 Aug;66(2):618-637. doi: 10.1016/j.jvs.2017.03.446. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	quality of image as the sole contrast agent to perform the needed interventions: Likert rating scale	Imaging from all cases were analyzed on conclusion of the study. The images were reviewed by two independent observers (radiologists with > 5 years of experience in performing endovascular procedures) blinded to treatment arm. Image quality was assessed using Likert rating scale ranging from 1 (very poor) to 5 (very good) for each image.	on conclusion of patient recruitment , image quality was aseessed within 12 weeks
Secondary	technical success rate	surgical results with completion of the intended procedure.	immediate post operative
Secondary	Incidence of Procedure-related complications .	defined as the freedom from procedural complications (Procedure-related complications were the incidence of cardiac death, myocardial infarction, stroke, major amputation, non-occlusive mesenteric ischemia, extended hospitalization (> 24 hours) as a consequence of CO2-guided treatment, hematomas, pseudo-aneurysms, perforations, contrast induced nephropathy (CIN), target lesion revascularization and postoperative death within 3 months of surgery,)	1year follow up